Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02869802 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis

Study acronym: PanGen
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Dec 2026 → Dec 2027
See other at-risk trials from British Columbia Cancer Agency

Record History

  1. Primary completion pushed from Dec 2026 to Dec 2027 Completion pushed from Dec 2027 to Dec 2028 · Site details revised at 1 of 4 sitesv11 Show 2 more changesShow less
    • Completion pushed from Dec 2027 to Dec 2028
    • Site details revised at 1 of 4 sites
  2. Study description expanded, about 17 wordsv10 See this version in full on ClinicalTrials.gov ↗
  3. Primary completion date: Dec 2023 to Dec 2026 Completion date: Dec 2024 to Dec 2027v9 Show 1 more changeShow less
    • Completion date: Dec 2024 to Dec 2027
  4. Site details revised at 1 of 4 sites Collaborators: 3 to 4v8 Show 1 more changeShow less
    • Collaborators: 3 to 4

    See this version in full on ClinicalTrials.gov ↗

  5. Primary completion date: Sep 2023 to Dec 2023 Completion date: Sep 2023 to Dec 2024v7 Show 1 more changeShow less
    • Completion date: Sep 2023 to Dec 2024
Show 5 earlier versionsHide 5 earlier versions
  1. Interventions: Serial Collection of Plasma and Serum and Urine Samples (Other), Tumour Biopsy (Procedure) to Serial Collection of Plasma and Serum Samples (Other), Tumour Biopsy (Procedure) Eligibility criteria shortened, about 6 words · Study description expanded, about 72 words · Site details revised at 1 of 4 sites · 1 morev6 Show 4 more changesShow less
    • Eligibility criteria shortened, about 6 words
    • Study description expanded, about 72 words
    • Site details revised at 1 of 4 sites
    • Publications: 33 to 38

    See this version in full on ClinicalTrials.gov ↗

  2. Start date: Sep 2016 to Oct 6, 2016 Site details revised at 3 of 4 sitesv5 Show 1 more changeShow less
    • Site details revised at 3 of 4 sites
  3. Enrollment target: 120 to 190 Primary completion date: Sep 2019 to Sep 2023 · Study sites: 1 to 4 · Completion date: Sep 2021 to Sep 2023 · 2 morev4 Show 5 more changesShow less
    • Primary completion date: Sep 2019 to Sep 2023
    • Study sites: 1 to 4
    • Completion date: Sep 2021 to Sep 2023
    • Interventions: Serial Collection of Plasma, Serum and Urine Samples (Other), Tumour Biopsy (Procedure) to Serial Collection of Plasma and Serum and Urine Samples (Other), Tumour Biopsy (Procedure)
    • Study description expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  4. Completion date: Sep 2021v3
  5. Trial status: Not Yet Recruiting to Recruiting Site details revisedv2 Show 1 more changeShow less
    • Site details revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Researchers are looking for better ways of understanding and treating pancreatic cancer. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour. These characteristics may be useful in choosing treatments for patients in the future. Changes (mutations) in genes have been shown to be an important characteristic in cancers. Looking at differences in genes in patients with advanced pancreatic ductal adenocarcinomas and comparing this information with response to their initial chemotherapy treatment may help to learn which treatments may be better for certain patients after initial treatment.
Trial Details
NCT Number NCT02869802
Lead Sponsor British Columbia Cancer Agency
Collaborators: Terry Fox Research Institute, BC Cancer Foundation, Pancreas Centre BC, American Society of Clinical Oncology
Conditions Cancer, Pancreatic Cancer
Enrollment 190 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov